Volume 35, Issue 6 p. 1354-1356
CASE REPORT

TEG improves anticoagulation management during cardiopulmonary bypass complicated by antiphospholipid syndrome

Tomomi Nakajima MD

Department of Cardiovascular Surgery, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan

Search for more papers by this author
Hideyuki Kato MD, PhD

Department of Cardiovascular Surgery, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan

Search for more papers by this author
Bryan J. Mathis PhD

Department of Cardiovascular Surgery, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan

Search for more papers by this author
Yuji Hiramatsu MD, PhD

Department of Cardiovascular Surgery, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan

Search for more papers by this author
Hiroaki Sakamoto MD, PhD

Corresponding Author

Department of Cardiovascular Surgery, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan

Correspondence Hiroaki Sakamoto, MD, PhD, Department of Cardiovascular Surgery, Faculty of Medicine, University of Tsukuba, 1‐1‐1 Tennodai, Tsukuba 305‐8575, Japan.

Email: sakamotoh@md.tsukuba.ac.jp

Search for more papers by this author
First published: 17 April 2020
Citations: 1

Abstract

Background and Aim

Cardiopulmonary bypass (CPB) in antiphospholipid syndrome (APS) patients carries a high risk of thrombosis and hemorrhage. However, optimal anticoagulation surveillance methods have not been established and heparin optimization has not yet been totally validated as reflective of anticoagulation status.

Methods and Result

Here, a 45‐year‐old female with APS underwent mitral valvuloplasty due to infective endocarditis. We used a perioperative, in vitro, heparin‐activated clotting time (ACT) titration line coupled with synergistic, intraoperative thromboelastography (TEG) to monitor coagulation activity. After the ACT target was reached, TEG monitored the suppression of both intrinsic and extrinsic coagulation activity throughout the surgery.

Conclusion

TEG thus provided valuable temporal information on both intrinsic and extrinsic coagulation suppression validating heparin‐ACT titration targets.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.